Synthesize Bio: Seattle AI Profile — Product, Footprint & Verified Record

Modern Seattle computational biology and life-sciences research laboratory overlooking Pacific Northwest evergreens

About Will

I run Tygart Media, an AI-first agency that gets businesses cited and recommended by AI assistants — and I write about what we do, including what breaks.

Connect on LinkedIn →
Washington AI Companies Census · Verified Record (November 19, 2026)
Sourced Baseline: As of November 19, 2026, Synthesize Bio operates as an independent, Seed-stage Seattle computational biology startup at synthesize.bio. Spun out of Fred Hutchinson Cancer Center in 2023 by co-founders Jeff Leek, PhD, and Robert Bradley, PhD, the company raised a $10M Seed round led by Madrona Venture Group in September 2025 and builds generative genomics foundation models (GEM-1) and the VERDICT platform to simulate human biology and forecast clinical trial outcomes for biopharma teams.
PROFILE BRIEF · HOUSE PDF & MARKDOWN TWIN
Synthesize Bio — Seattle AI Profile
Download the formatted 2-page profile brief (PDF) or open the single-source Markdown twin for Synthesize Bio. Every claim below links to its verified primary source.

What Synthesize Bio Builds

Synthesize Bio develops generative genomics foundation models and clinical prediction software—positioned on its official website as "Virtual Human Models for Clinical Prediction"—to simulate hypothetical biology experiments before wet-lab studies or human trials are executed. Its core GEM model family (introduced publicly with GEM-1 and an accompanying September 2025 bioRxiv preprint) learns from harmonized human RNA-sequencing and single-cell data to predict gene expression responses across healthy and diseased cells and tissues (GeekWire, Sep 16, 2025).

On top of those generative expression models, Synthesize Bio builds VERDICT, a platform that uses simulated human biology to evaluate drug candidates and forecast clinical trial outcomes—covering statistical significance, treatment-arm direction, effect size, and serious adverse events. As co-founder Robert Bradley told GeekWire, biopharma and academic scientists regularly face costly go-or-no-go decisions with incomplete information; Synthesize Bio's goal is to give teams computational feedback earlier in R&D rather than replacing wet-lab science.

  • GEM generative expression models: Trained on company-stated datasets spanning 800,000 bulk RNA-seq samples, 400M single cells, 22,300 unique perturbation contexts, 50+ human tissues, and 40+ therapeutic areas (synthesize.bio).
  • VERDICT clinical trial prediction: Incorporates 12,418 labelled clinical trials to forecast endpoint success, treatment direction, effect size, and serious adverse event risk for asset evaluation and trial design.
  • Retrospective validation benchmark: On synthesize.bio, Synthesize Bio reports that across 1,717 held-out later clinical trials, trials VERDICT predicted as successful achieved a 70% observed success rate compared with 52% across all evaluated trials (a 35% relative gain in meeting at least one significant primary endpoint).
Synthesize Bio — Verified Washington AI Snapshot
Verified profile snapshot for Synthesize Bio (Seattle, WA) as of November 19, 2026.
FieldVerified Record (As of Nov 19, 2026)
CompanySynthesize Bio
Official Websitehttps://www.synthesize.bio/
Washington HQSeattle, WA
Other WA FootprintFred Hutchinson Cancer Center spinout; backed by Seattle's Madrona Venture Group and AI2 Incubator
Founded2023 (GeekWire, Sep 16, 2025)
Founders / LeadershipJeff Leek, PhD (Co-Founder & CEO), Robert Bradley, PhD (Co-Founder & SAB Chair), Ariel Brumbaugh (Senior Director of Business Development)
StageSeed
Announced Funding$10M Seed round (Sep 2025; led by Madrona Venture Group with AI2 Incubator, Sahsen Ventures, Inner Loop Capital, and Point Field Partners)
Team Size16 employees (GeekWire, Sep 16, 2025); live site highlights 11 PhD scientists plus co-founders
Primary Ecosystem TiesFred Hutchinson Cancer Center; Madrona Venture Group; AI2 Incubator / AI House; 2026 GeekWire Awards AI Innovation finalist

Washington Footprint and Leadership

Synthesize Bio is headquartered in Seattle, Washington, originating as a 2023 spinout from Fred Hutchinson Cancer Center (GeekWire, Sep 16, 2025). The company maintains its canonical web presence at https://www.synthesize.bio/ (its company page details the founding team and scientific staff, while an alternate .com address returns HTTP 403). No public street address is disclosed on the live site.

Co-founder and CEO Jeff Leek, PhD served as Chief Data Officer and J. Orin Edson Foundation Endowed Chair at Fred Hutch, was named a TIME100 AI 2025 honoree, received the Presidents' Award for top statistician under 40, and created open-source genomics software downloaded over 1.4 million times (synthesize.bio). Co-founder and Scientific Advisory Board Chair Robert Bradley, PhD directed Fred Hutch's Translational Data Science Integrated Research Center, held the McIlwain Family Endowed Chair, conducted research on how faulty RNA splicing drives cancer, and previously co-founded Codify Therapeutics. In October 2025, Synthesize Bio hired Ariel Brumbaugh from Gladstone Institutes as Senior Director of Business Development (GeekWire Tech Moves, Oct 23, 2025). GeekWire reported a 16-person team at the September 2025 launch, and the live site highlights 11 PhD scientists with backgrounds at BMS, J&J, Recursion, Novo, Pathos, Freenome, and Genentech.

Aerial view of the Greater Seattle and Bellevue Lake Washington technology corridor with Mount Rainier on the horizon
Washington AI ecosystem context: Aerial view of the Greater Seattle and Bellevue Lake Washington technology corridor with Mount Rainier on the horizon.

Products, Users, and Public Traction

Synthesize Bio builds for biopharmaceutical drug development teams, clinical trial designers, and biotech asset and investment evaluators seeking earlier signals on whether therapeutic candidates that pass safety checks are likely to demonstrate clinical efficacy. The company maintains a Trust Center and states a SOC 2 compliance posture on synthesize.bio.

Specific biopharma customer names, partnership contracts, and commercial revenue figures are not publicly disclosed. Public ecosystem validation includes selection as a finalist for AI Innovation of the Year at the 2026 GeekWire Awards (alongside Avante, ConverzAI, Envive AI, and Spangle AI) and presenting to national venture investors at Seattle's AI House Demo Day on Pier 70 in September 2026.

Funding, Stage, and Place in Washington's AI Landscape

Synthesize Bio is a Seed-stage startup that emerged from stealth in September 2025 with a $10M Seed round led by Seattle's Madrona Venture Group (GeekWire, Sep 16, 2025), joined by AI2 Incubator, Sahsen Ventures, Inner Loop Capital, and Point Field Partners. No subsequent Series A round or acquisition has been publicly disclosed through November 2026.

Within Seattle's life-sciences AI corridor, Synthesize Bio sits directly at the bridge between the city's biomedical research institutions and its applied AI investor base. Alongside Fred Hutch, the University of Washington's Institute for Protein Design, and local biotech AI peers applying foundation models to cell biology and automated lab execution, Synthesize Bio represents a Seattle thesis centered on computational biology models trained on large-scale public and clinical genomics datasets.

Related Washington AI Profiles & Tygart Media Context

Verified Primary Sources

Get The Signal

What we actually ran, what it measured, and what it means for a restoration shop — every week, including the flops.

Subscription Form

Track the AI tools you actually use
Vendor-neutral prices & limits for ChatGPT, Claude, Gemini, Perplexity and more — tracked in AI Stack Watch.
See the live AI tracker →or set up your alerts

Comments

Leave a Reply

Your email address will not be published. Required fields are marked *